A service of StreetInsider.com
Ticker Symbol
Welcome

Most Popular

AAPL 493.17
C 33.66
GOOG 611.46
BAC 8.18
RIMM 15.90

Recently Added

CPIC 1.19
SHMX 0.00
NBTH 12.50
COHO 0.00
PZZI 4.71

Gaining Speed

COHO 0.00
SHMX 0.00
CPIC 1.19
NBTH 12.50
AVEW 0.00
8.60 +0.00 (0.00%) SPA

Click Here to Receive Instant E-mail and RSS Alerts


Trade SPA now with

Stock Details

Last Trade:8.60 Change:+0.00 (0.00%) Prev Close:8.60 Open: 8.58 Days Range:8.45 – 8.75 52 Week Range: 5.34 - 10.88 Volume:37818 P/E: 17.55
EPS:0.49





Recent Blog Posts

Blog Posts on 02/08/12 at 6:27pm
Sparton Corporation's CEO Discusses Q4 2011 Results - Q&A Transcript
Blog Posts on 01/05/12 at 6:20pm
2 Sectors To Consider If Romney Wins
Blog Posts on 11/10/11 at 1:14pm
Sparton's CEO Discusses F1Q2012 (Qtr End 9/30/11) Results - Earnings Call Transcript
Blog Posts on 11/08/11 at 7:30am
Sparton Corp.: Strong Q4 Operating Results Bode Well For Q1
Blog Posts on 11/07/11 at 11:25am
Exelixis: Setting The Facts Straight
Blog Posts on 11/01/11 at 2:30pm
Exelixis' Curious And Risky Strategy
Blog Posts on 10/29/11 at 3:25pm
20 Rallying Companies Releasing Earnings Next Week Undervalued By Graham
Blog Posts on 09/08/11 at 4:12pm
Sparton Corporation's CEO Discusses F4Q 2011 Results - Q&A Transcript
Blog Posts on 08/29/11 at 4:32am
Sparton Sell-Off Presents Attractive Valuation And Rebound Opportunity
Blog Posts on 07/29/11 at 12:32pm
Raptor Pharmaceuticals Announces Positive Phase 3 Trial Results: Shares Tumble
Blog Posts on 05/12/11 at 6:53pm
Sparton Corporation's CEO Discusses Q1 2011 Results - Q&A Transcript
Blog Posts on 03/23/11 at 3:02pm
Historical Trial Data Bodes Well for Amarin
Blog Posts on 03/01/11 at 2:59pm
Sell Off Creates Opportunity in Aastrom Bio
Blog Posts on 02/23/11 at 11:30am
Why AEterna Zentaris Still Retains 200% to 300% Upside Potential
Blog Posts on 02/17/11 at 9:08am
Undervalued Apricus Bio Poised to Follow Threshold Pharma in Receiving SPA Approval
Blog Posts on 02/15/11 at 4:26pm
Sparton Corporation CEO Discusses F2Q2011 Results - Earnings Call Question and Answer Session Transcript
Blog Posts on 02/08/11 at 4:56pm
Maximizing Opportunity and Minimizing Risk With Trading FDA Decisions
Blog Posts on 02/02/11 at 10:42am
FDA Catalyst Trade: Protalix BioTherapeutics
Blog Posts on 01/26/11 at 6:16pm
13 Above Average Stocks: Industry Leaders or Boat Anchors in Disguise?
Blog Posts on 01/19/11 at 4:24pm
Ariad Pharmaceuticals Scores With SUCCEED
Blog Posts on 11/17/10 at 4:39pm
Sparton CEO Discusses F1Q2011 Results - Earnings Call Transcript
Blog Posts on 11/08/10 at 8:24am
3 Upcoming FDA Decisions to Watch Closely
Blog Posts on 10/27/10 at 6:26am
Sparton: Turnaround Team Returns Micro-Cap Manufacturer to Profitability
Blog Posts on 09/21/10 at 4:13am
Sparton: Delphi Medical Acquisition Should Be Highly Accretive
Blog Posts on 09/19/10 at 9:39am
Keryx Remains a Focused, Well-Funded Bio-Pharma Play
Blog Posts on 09/07/10 at 2:36am
Sparton: Delphi Medical Acquisition Should Be Highly Accretive
Blog Posts on 07/22/10 at 8:44am
The Value of an SPA for Avanir Pharmaceuticals
Blog Posts on 07/14/10 at 5:15pm
Sparton: An Undiscovered Turnaround
Blog Posts on 05/20/10 at 12:58pm
Sparton Corporation F3Q10 (Qtr End 03/31/10) Earnings Call Transcript (Prepared Comments)
Blog Posts on 05/18/10 at 2:29pm
Sparton Corporation F3Q10 (Qtr End 03/31/10) Earnings Call Transcript